Current Headlines

  1. Sartorius Stedim Offers New Crossflow Filtration System For Process Development
    2/8/2016

    Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, announces the launch of SARTOFLOW Smart, the smart and easy benchtop crossflow system for optimized ultra- and diafiltration applications.

  2. Sangamo Announces FDA Clearance Of Investigational New Drug Application
    2/8/2016

    Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I).

  3. Marken The Preferred Partner To Fight Zika Virus
    2/8/2016

    Marken announced recently they are working with key pharma partners in the race to find a vaccine and treatment for the Zika virus, declared as a public health emergency by the World Health Organization (WHO) earlier this week.

  4. Ametek Announces Two Acquisitions
    2/5/2016

    Brookfield Engineering Broadens AMETEK’s Laboratory Instrumentation Platform ESP/SurgeX Expands AMETEK’s Power Protection Platform

  5. ATCC Supporting Zika Virus Research
    2/5/2016

    ATCC, the premier global biological materials resource and standards organization, is poised to assist the medical and life science researchers that are working to address the evolving concerns around Zika Virus infection.

  6. Amarantus Requests Rare Pediatric Disease Designation From FDA
    2/5/2016

    Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) from the US Food and Drug Administration (FDA) for treating retinitis pigmentosa (RP) with MANF.

  7. Biosimilars Forum Issues Statement Regarding House Energy & Commerce, Subcommittee on Health Biosimilars Hearing, Launch of New Biosimilars Education Initiative
    2/4/2016

    The Biosimilars Forum – the nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States – issued the following statement about the Biosimilars hearing before the House Energy and Commerce, Subcommittee on Health and the launch of a new biosimilars education initiative.

  8. Beike Biotechnology To Supply 11 Hospitals With Cell Therapy
    2/4/2016

    Beike Biotechnology, the Shenzhen local government, and various medical institutions attended a ceremony in late 2015 to mark their successful combined efforts to provide integrative, personalized cell therapy in 2016.

  9. Phase 3 Study Of BLINCYTO Met Primary Endpoint Of Increased Survival
    2/4/2016

    Amgen (NASDAQ: AMGN) today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study.

  10. Amgen Announces Positive Results From Phase 3 GAUSS-3 Trial Of Repatha
    2/4/2016

    Amgen (NASDAQ: AMGN) today announced that the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) trial evaluating Repatha® (evolocumab) in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints: mean percent reductions from baseline in low-density lipoprotein cholesterol (LDL-C) at weeks 22 and 24, and the percent reduction from baseline in LDL-C at week 24.